Refraction

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Mercoledì, Marzo 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients

Retrieved on: 
Mercoledì, Marzo 13, 2024
Biotechnology, Pharmaceutical, Optical, Health, International Society, Partnership, DES, ASCRS, Patient, Ophthalmology, Surface, University, Dry, MD, Refraction, Cataract, Eye, Mycophenolic acid, Society, Dry eye syndrome, Lead, Pharmaceutical industry

Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.

Key Points: 
  • Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.
  • A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A.
  • Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.
  • Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989.

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Giovedì, Febbraio 1, 2024
Principal, Public key certificate, Cordis, MD, Society, FDA, Columbia University, International Society, Book, Family, American Academy, Cataract, Don, Lehigh University, Culture, University, Refraction, ASCRS, Refractive surgery, Growth, American College, Mount Sinai Medical Center, Publication, Wills Eye Hospital, CFO, Congress, Therapy, Eye surgery, MBA, Executive, Accounting

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

Refract Technologies unveils AXIS Lite, the newest VR accessory for gamers and creators

Retrieved on: 
Giovedì, Gennaio 25, 2024
VRChat, Lite, AXIS, Multimedia, OpenVR, Ship, Refraction, Sale, Movement, Steam (service), VR, Blade and Sorcery, Unreal Engine, Zenith, Video game

SINGAPORE, Jan. 25, 2024 /PRNewswire/ -- Refract Technologies today unveils the newest addition to its roster - AXIS Lite. To celebrate its reveal, Refract is opening up global pre-sale orders on 8 February ahead of its late Spring launch, allowing VR enthusiasts and gamers to secure the latest piece of immersive technology.

Key Points: 
  • The all-new four-node motion tracker, AXIS Lite, is available globally to pre-order starting 8 February 2024 and will ship in May 2024
    SINGAPORE, Jan. 25, 2024 /PRNewswire/ -- Refract Technologies today unveils the newest addition to its roster - AXIS Lite.
  • AXIS Lite tracks real-time lower body movement in addition to the upper body tracking typical of VR headsets and controllers, allowing for full-body immersion in VR.
  • The technology was created especially for consumers looking to take their VR gaming experiences to the next level with ease.
  • "At Refract, we believe VR has legs", said Michael Chng, Co-CEO of Refract Technologies.

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Retrieved on: 
Martedì, Novembre 7, 2023
Telecanthus, EEG microstates, Trial of the century, OMNI, LCD, WPS, Ophthalmology, Medicare, MIGS, Macs, Congress, IOP, Publication, GAAP, Nature, Environment, News, Growth, Cataract, Clinical trial, Surgeon, American Academy, Webcast, London, Refraction, European Society of Clinical Microbiology and Infectious Diseases, Centers for Medicare & Medicaid Services, Patient, GEMINI, Pharmaceutical industry, Video game, Ciclosporin

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.

Key Points: 
  • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
  • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
  • On October 26, 2023, WPS Government Health Administrators (“WPS”), a Medicare Administrative Contractor (“MAC”), published an LCD with an effective date of December 24, 2023.
  • Sight Sciences' management team will host a conference call today, November 7, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

MATI THERAPEUTICS ANNOUNCES PROMOTION OF CHRIS MULLER TO CHIEF OPERATING OFFICER

Retrieved on: 
Martedì, Settembre 26, 2023
Glaucoma, Refraction, Allergan, Inflammation, Amos Abbott, OTC, Optometry, FDA, Journal of Medical Marketing, Therapy, Mati, Pharmaceutical industry, Management

AUSTIN, Texas, Sept. 26, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has promoted Chris Muller to the position of Chief Operating Officer.  He formerly held the position of Chief Commercial Officer.  Mr Muller's expanded responsibilities include broad management of all operating activities, and preparation for and execution of the commercial launch of Mati's proprietary Evolute® sustained ocular drug delivery platform. 

Key Points: 
  • AUSTIN, Texas, Sept. 26, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has promoted Chris Muller to the position of Chief Operating Officer.
  • He formerly held the position of Chief Commercial Officer.
  • Chris has unique qualifications to help Mati achieve our development and commercialization goals, especially since our first three programs focus on the post-operative cataract market and glaucoma," said Bob Butchofsky, CEO of Mati.
  • Mr. Muller started his ophthalmic career at Allergan, where he held various positions of increasing responsibility from 1990 to 2005.

Dr. Evan Schoenberg Becomes The First Doctor In Georgia to Implant the IC-8® Apthera™ IOL

Retrieved on: 
Giovedì, Agosto 17, 2023
Optical, Health, Surgery, Medical Devices, Retina, Eye, Ageing, National Eye Institute, GLARE, IOL, Astigmatism, Patient, Face, Refraction, Hospital, Telescopic sight, Atlanta

Georgia Eye Partners is proud to share that Dr. Evan Schoenberg has become the first eye surgeon in the Atlanta metro area to implant the Apthera IOL, the first and only small aperture lens for cataract surgery.

Key Points: 
  • Georgia Eye Partners is proud to share that Dr. Evan Schoenberg has become the first eye surgeon in the Atlanta metro area to implant the Apthera IOL, the first and only small aperture lens for cataract surgery.
  • Some patients receive a monofocal IOL, which provides clear distance vision but leaves objects up close blurry.
  • The Apthera IOL is intended for use in just one eye and is paired with a monofocal or monofocal toric (astigmatism-correcting) IOL in the fellow eye.
  • Georgia Eye Partners remains committed to serving the growing aging population throughout Greater Atlanta and Georgia by implementing the latest and greatest advanced cataract surgery technologies and procedures.

Global Autonomous Last Mile Delivery Market Report 2023: Rise of the E-commerce Industry is Expected to Propel Growth

Retrieved on: 
Martedì, Luglio 11, 2023
Benchmark, DHL International Aviation ME, Food, Drink, DPDgroup, Health, DHL, India Brand Equity Foundation, Agriculture, COVID-19, Edron Academy, USD, Kiwi Campus, Sale, Amazon, Organization, Application, UAV, Growth, Transport, Geography, Refraction, Starship Technologies, Create, Flirtey, Software, Clothing, Fine chemical, Retail, Food delivery, Rail freight transport

DUBLIN, July 11, 2023 /PRNewswire/ -- The "Autonomous Last Mile Delivery Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 11, 2023 /PRNewswire/ -- The "Autonomous Last Mile Delivery Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the e-commerce industry is expected to propel the growth of the autonomous last-mile delivery market.
  • Global Autonomous Last Mile Delivery Market, Segmentation By Vehicle Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
    6.2.
  • Global Autonomous Last Mile Delivery Market, Segmentation By Solution, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
    6.3.

Pioneer of Refractive Surgery to Join Advisory Board of Evolution Optiks

Retrieved on: 
Mercoledì, Luglio 5, 2023
Advertising, Independent Payment Advisory Board, Refractive surgery, Refraction, 2016 EuroEyes Cyclassics, Visual impairment, Paratriathlon, University, Research, Medicine, Advisory board, Medical director, Ophthalmology, Knowledge, Cataract, Dentistry, Management

Evolution Optiks has developed a portable fully digital light field tele-refractor that enables eye exams to be conducted anywhere in the world, without the practitioner having to be present.

Key Points: 
  • Evolution Optiks has developed a portable fully digital light field tele-refractor that enables eye exams to be conducted anywhere in the world, without the practitioner having to be present.
  • His knowledge and guidance will help us to unlock the virtually endless possibilities of our light field technology", says Raul Mihali, President and CEO of Evolution Optiks.
  • "I am very excited to join the innovative and forward-thinking team of Evolution Optiks.
  • Founded in 2014, Evolution Optiks Limited specializes in light field technology and is on track to becoming a leader in digital innovation.

Pioneer of Refractive Surgery to Join Advisory Board of Evolution Optiks

Retrieved on: 
Mercoledì, Luglio 5, 2023
Advertising, Independent Payment Advisory Board, Refractive surgery, Refraction, 2016 EuroEyes Cyclassics, Visual impairment, Paratriathlon, University, Research, Medicine, Advisory board, Medical director, Ophthalmology, Knowledge, Cataract, Dentistry, Management

Evolution Optiks has developed a portable fully digital light field tele-refractor that enables eye exams to be conducted anywhere in the world, without the practitioner having to be present.

Key Points: 
  • Evolution Optiks has developed a portable fully digital light field tele-refractor that enables eye exams to be conducted anywhere in the world, without the practitioner having to be present.
  • His knowledge and guidance will help us to unlock the virtually endless possibilities of our light field technology", says Raul Mihali, President and CEO of Evolution Optiks.
  • "I am very excited to join the innovative and forward-thinking team of Evolution Optiks.
  • Founded in 2014, Evolution Optiks Limited specializes in light field technology and is on track to becoming a leader in digital innovation.